Business Context and Reporting Period
This Form 8-K reports the consummation of a business combination between BCTG Acquisition Corp. ("BCTG") and Tango Therapeutics, Inc. ("Old Tango") on August 10, 2021. Following the merger, BCTG changed its name to Tango Therapeutics, Inc. ("New Tango") and began trading on the Nasdaq Capital Market under the symbol "TNGX" on August 11, 2021. New Tango is a precision oncology company focused on developing therapies targeting tumor suppressor gene loss.
Key Financial Metrics and Capital Structure
PIPE Financing: The Company raised aggregate gross proceeds of $186,100,000 through the sale of 18,610,000 shares of Common Stock to PIPE Investors at $10.00 per share.
Redemptions: Prior to the closing, holders of 1,106,814 shares of BCTG common stock exercised their right to redeem shares for approximately $11.1 million in aggregate cash payments.
Capitalization Post-Closing: Immediately following the transactions, there were 87,474,258 shares of Common Stock outstanding. Additionally, 9,498,725 shares were subject to equity awards under the 2021 Stock Option and Incentive Plan.
Equity Conversion: Old Tango common stock was converted into New Tango Common Stock at a ratio of approximately 0.34 shares of New Tango for each share of Old Tango. Old Tango equity awards were exchanged based on an implied equity value of $550,000,000.
Financial Statements: Specific revenue, profit, cash flow, and debt figures for the reporting period are not contained in the text of this 8-K. The filing references the Proxy Statement/Prospectus and attached exhibits (Exhibits 99.1, 99.2, 99.3, and 99.4) for historical and pro forma financial data.
Material Changes and Corporate Actions
- Change in Control: The merger resulted in a change of control, with New Tango ceasing to be a shell company.
- Accountant Change: The Audit Committee dismissed WithumSmith+Brown, PC as the independent registered public accounting firm and appointed PricewaterhouseCoopers LLP ("PwC") effective August 10, 2021.
- Board Composition: The Board was reconstituted with seven new directors divided into three staggered classes. New standing committees (Audit, Compensation, and Nominating and Corporate Governance) were established.
- Stockholder Approval: BCTG stockholders approved the Business Combination, Charter Amendments, and Equity Incentive Plans at a special meeting on August 9, 2021.
Guidance, Outlook, and Pipeline
Management outlined a strategy to advance three primary product candidates:
- TNG908 (PRMT5 Inhibitor): Designed for cancers with MTAP deletion. The Company plans to file an Investigational New Drug (IND) application in the fourth quarter of 2021 and initiate a Phase 1/2 clinical trial in the first half of 2022.
- USP1 Inhibitor: Targeting BRCA1-mutant cancers. The Company anticipates filing an IND in 2022.
- Target 3 (STK11-mutant Lung Cancer): An undisclosed target aimed at reversing immune evasion. The Company expects to advance a clinical candidate into IND-enabling studies in the second half of 2022 and file an IND in 2023.
Collaboration: The Company maintains a collaboration with Gilead Sciences Inc. to identify and develop immune evasion targets, excluding the lead PRMT5 program and USP1 program.
Risks: The filing includes standard forward-looking statement disclaimers regarding the success of clinical trials, regulatory approvals, and funding. Specific risk factors are incorporated by reference from the Proxy Statement/Prospectus.
Investor Verification Checklist
- Verify the pro forma financial condition and liquidity position in Exhibit 99.4 (Unaudited Pro Forma Condensed Combined Financial Information).
- Review the full text of the Merger Agreement (Exhibit 2.1) for specific terms regarding the conversion ratio and treatment of equity awards.
- Confirm the status of the registration statement for the resale of PIPE Financing Shares, which must be filed within 30 days of the closing.
- Examine the "Risk Factors" section of the Proxy Statement/Prospectus for details on clinical trial risks and regulatory hurdles.
- Check the 2021 Stock Option and Incentive Plan (Exhibit 10.4) for the initial share reserve of 9,498,725 shares and the annual increase mechanism.